351
|
Liu X, Zhou C, Zhao Y, Zhou S, Wang W, Zhou DX. The rice enhancer of zeste [E(z)] genes SDG711 and SDG718 are respectively involved in long day and short day signaling to mediate the accurate photoperiod control of flowering time. Front Plant Sci 2014; 5:591. [PMID: 25400654 PMCID: PMC4215622 DOI: 10.3389/fpls.2014.00591] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/02/2014] [Accepted: 10/10/2014] [Indexed: 05/19/2023]
Abstract
Recent advances in rice flowering studies have shown that the accurate control of flowering by photoperiod is regulated by key mechanisms that involve the regulation of flowering genes including Heading date1 (Hd1), Early hd1 (Ehd1), Hd3a, and RFT1. The chromatin mechanism involved in the regulation of rice flowering genes is presently not well known. Here we show that the rice enhancer of zeste [E(z)] genes SDG711 and SDG718, which encode the polycomb repressive complex2 (PRC2) key subunit that is required for trimethylation of histone H3 lysine 27 (H3K27me3), are respectively, involved in long day (LD) and short day (SD) regulation of key flowering genes. The expression of SDG711 and SDG718 is induced by LD and SD, respectively. Over-expression and down-regulation of SDG711 respectively, repressed and promoted flowering in LD, but had no effect in SD. By contrast, down-regulation of SDG718 had no effect in LD but delayed flowering in SD. SDG711 and SDG718 repressed OsLF (a repressor of Hd1) respectively in LD and SD, leading to a higher expression of Hd1 thus late flowering in LD and early flowering in SD. SDG711 was also found to be involved in the repression of Ehd1 in LD. SDG711 was shown to directly target to OsLF and Ehd1 loci to mediate H3K27me3 and gene repression. The function of the rice E(z) genes in LD repression and SD promotion of flowering suggests that PRC2-mediated epigenetic repression of gene expression is involved in the accurate photoperiod control of rice flowering.
Collapse
Affiliation(s)
- Xiaoyun Liu
- National Key Laboratory of Crop Genetic Improvement, Huazhong Agricultural UniversityWuhan, China
| | - Chao Zhou
- National Key Laboratory of Crop Genetic Improvement, Huazhong Agricultural UniversityWuhan, China
| | - Yu Zhao
- National Key Laboratory of Crop Genetic Improvement, Huazhong Agricultural UniversityWuhan, China
| | - Shaoli Zhou
- National Key Laboratory of Crop Genetic Improvement, Huazhong Agricultural UniversityWuhan, China
| | - Wentao Wang
- National Key Laboratory of Crop Genetic Improvement, Huazhong Agricultural UniversityWuhan, China
| | - Dao-Xiu Zhou
- National Key Laboratory of Crop Genetic Improvement, Huazhong Agricultural UniversityWuhan, China
- Institut de Biologie des Plantes, UMR8618, Université Paris-Sud 11Orsay, France
- *Correspondence: Dao-Xiu Zhou, Institut de Biologie des Plantes, UMR8618, Université Paris-Sud 11, 90405 Orsay, France e-mail:
| |
Collapse
|
353
|
He Y, Meng XM, Huang C, Wu BM, Zhang L, Lv XW, Li J. Long noncoding RNAs: Novel insights into hepatocelluar carcinoma. Cancer Lett 2013; 344:20-27. [PMID: 24183851 DOI: 10.1016/j.canlet.2013.10.021] [Citation(s) in RCA: 320] [Impact Index Per Article: 29.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2013] [Revised: 10/18/2013] [Accepted: 10/23/2013] [Indexed: 02/07/2023]
Abstract
Recent advances in non-protein coding part of human genome analysis have discovered extensive transcription of large RNA transcripts that lack of coding protein function, termed long noncoding RNAs (lncRNAs). It is becoming evident that lncRNAs may be an important class of pervasive genes involved in carcinogenesis and metastasis. However, the biological and molecular mechanisms of lncRNAs in diverse diseases are not yet fully understood. Thus, it is anticipated that more efforts should be made to clarify the lncRNAs world. Moreover, accumulating studies have demonstrated that a class of lncRNAs are dysregulated in hepatocellular carcinoma(HCC) and closely related with tumorigenesis, metastasis, prognosis or diagnosis. In this review, we will briefly discuss the regulation and functional role of lncRNAs in HCC, therefore evaluating the potential of lncRNAs as prospective novel therapeutic targets in HCC.
Collapse
Affiliation(s)
- Yong He
- School of Pharmacy, Anhui Key Laboratory of Bioactivity of Natural Products, Anhui Medical University, Hefei 230032, China; The Key Laboratory of Anti-Inflammatory and Immune Medicine (Anhui Medical University), Ministry of Education, China; Institute for Liver Diseases of Anhui Medical University (ILD-AMU), Anhui Medical University, Hefei 230032, China
| | - Xiao-Ming Meng
- School of Pharmacy, Anhui Key Laboratory of Bioactivity of Natural Products, Anhui Medical University, Hefei 230032, China; The Key Laboratory of Anti-Inflammatory and Immune Medicine (Anhui Medical University), Ministry of Education, China; Institute for Liver Diseases of Anhui Medical University (ILD-AMU), Anhui Medical University, Hefei 230032, China
| | - Cheng Huang
- School of Pharmacy, Anhui Key Laboratory of Bioactivity of Natural Products, Anhui Medical University, Hefei 230032, China; The Key Laboratory of Anti-Inflammatory and Immune Medicine (Anhui Medical University), Ministry of Education, China; Institute for Liver Diseases of Anhui Medical University (ILD-AMU), Anhui Medical University, Hefei 230032, China
| | - Bao-Ming Wu
- School of Pharmacy, Anhui Key Laboratory of Bioactivity of Natural Products, Anhui Medical University, Hefei 230032, China; The Key Laboratory of Anti-Inflammatory and Immune Medicine (Anhui Medical University), Ministry of Education, China; Institute for Liver Diseases of Anhui Medical University (ILD-AMU), Anhui Medical University, Hefei 230032, China
| | - Lei Zhang
- School of Pharmacy, Anhui Key Laboratory of Bioactivity of Natural Products, Anhui Medical University, Hefei 230032, China; The Key Laboratory of Anti-Inflammatory and Immune Medicine (Anhui Medical University), Ministry of Education, China; Institute for Liver Diseases of Anhui Medical University (ILD-AMU), Anhui Medical University, Hefei 230032, China
| | - Xiong-Wen Lv
- School of Pharmacy, Anhui Key Laboratory of Bioactivity of Natural Products, Anhui Medical University, Hefei 230032, China; The Key Laboratory of Anti-Inflammatory and Immune Medicine (Anhui Medical University), Ministry of Education, China; Institute for Liver Diseases of Anhui Medical University (ILD-AMU), Anhui Medical University, Hefei 230032, China
| | - Jun Li
- School of Pharmacy, Anhui Key Laboratory of Bioactivity of Natural Products, Anhui Medical University, Hefei 230032, China; The Key Laboratory of Anti-Inflammatory and Immune Medicine (Anhui Medical University), Ministry of Education, China; Institute for Liver Diseases of Anhui Medical University (ILD-AMU), Anhui Medical University, Hefei 230032, China.
| |
Collapse
|
368
|
Verma SK, Tian X, LaFrance LV, Duquenne C, Suarez DP, Newlander KA, Romeril SP, Burgess JL, Grant SW, Brackley JA, Graves AP, Scherzer DA, Shu A, Thompson C, Ott HM, Aller GSV, Machutta CA, Diaz E, Jiang Y, Johnson NW, Knight SD, Kruger RG, McCabe MT, Dhanak D, Tummino PJ, Creasy CL, Miller WH. Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. ACS Med Chem Lett 2012; 3:1091-6. [PMID: 24900432 DOI: 10.1021/ml3003346] [Citation(s) in RCA: 284] [Impact Index Per Article: 23.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2012] [Accepted: 10/11/2012] [Indexed: 12/31/2022] Open
Abstract
The histone H3-lysine 27 (H3K27) methyltransferase EZH2 plays a critical role in regulating gene expression, and its aberrant activity is linked to the onset and progression of cancer. As part of a drug discovery program targeting EZH2, we have identified highly potent, selective, SAM-competitive, and cell-active EZH2 inhibitors, including GSK926 (3) and GSK343 (6). These compounds are small molecule chemical tools that would be useful to further explore the biology of EZH2.
Collapse
Affiliation(s)
- Sharad K. Verma
- Cancer
Epigenetics Discovery Performance Unit, Oncology Research & Development, ‡Protein Dynamics
Discovery Performance Unit, Oncology Research & Development, and §Platform Technology
and Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, United States
| | - Xinrong Tian
- Cancer
Epigenetics Discovery Performance Unit, Oncology Research & Development, ‡Protein Dynamics
Discovery Performance Unit, Oncology Research & Development, and §Platform Technology
and Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, United States
| | - Louis V. LaFrance
- Cancer
Epigenetics Discovery Performance Unit, Oncology Research & Development, ‡Protein Dynamics
Discovery Performance Unit, Oncology Research & Development, and §Platform Technology
and Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, United States
| | - Céline Duquenne
- Cancer
Epigenetics Discovery Performance Unit, Oncology Research & Development, ‡Protein Dynamics
Discovery Performance Unit, Oncology Research & Development, and §Platform Technology
and Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, United States
| | - Dominic P. Suarez
- Cancer
Epigenetics Discovery Performance Unit, Oncology Research & Development, ‡Protein Dynamics
Discovery Performance Unit, Oncology Research & Development, and §Platform Technology
and Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, United States
| | - Kenneth A. Newlander
- Cancer
Epigenetics Discovery Performance Unit, Oncology Research & Development, ‡Protein Dynamics
Discovery Performance Unit, Oncology Research & Development, and §Platform Technology
and Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, United States
| | - Stuart P. Romeril
- Cancer
Epigenetics Discovery Performance Unit, Oncology Research & Development, ‡Protein Dynamics
Discovery Performance Unit, Oncology Research & Development, and §Platform Technology
and Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, United States
| | - Joelle L. Burgess
- Cancer
Epigenetics Discovery Performance Unit, Oncology Research & Development, ‡Protein Dynamics
Discovery Performance Unit, Oncology Research & Development, and §Platform Technology
and Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, United States
| | - Seth W. Grant
- Cancer
Epigenetics Discovery Performance Unit, Oncology Research & Development, ‡Protein Dynamics
Discovery Performance Unit, Oncology Research & Development, and §Platform Technology
and Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, United States
| | - James A. Brackley
- Cancer
Epigenetics Discovery Performance Unit, Oncology Research & Development, ‡Protein Dynamics
Discovery Performance Unit, Oncology Research & Development, and §Platform Technology
and Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, United States
| | - Alan P. Graves
- Cancer
Epigenetics Discovery Performance Unit, Oncology Research & Development, ‡Protein Dynamics
Discovery Performance Unit, Oncology Research & Development, and §Platform Technology
and Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, United States
| | - Daryl A. Scherzer
- Cancer
Epigenetics Discovery Performance Unit, Oncology Research & Development, ‡Protein Dynamics
Discovery Performance Unit, Oncology Research & Development, and §Platform Technology
and Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, United States
| | - Art Shu
- Cancer
Epigenetics Discovery Performance Unit, Oncology Research & Development, ‡Protein Dynamics
Discovery Performance Unit, Oncology Research & Development, and §Platform Technology
and Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, United States
| | - Christine Thompson
- Cancer
Epigenetics Discovery Performance Unit, Oncology Research & Development, ‡Protein Dynamics
Discovery Performance Unit, Oncology Research & Development, and §Platform Technology
and Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, United States
| | - Heidi M. Ott
- Cancer
Epigenetics Discovery Performance Unit, Oncology Research & Development, ‡Protein Dynamics
Discovery Performance Unit, Oncology Research & Development, and §Platform Technology
and Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, United States
| | - Glenn S. Van Aller
- Cancer
Epigenetics Discovery Performance Unit, Oncology Research & Development, ‡Protein Dynamics
Discovery Performance Unit, Oncology Research & Development, and §Platform Technology
and Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, United States
| | - Carl A. Machutta
- Cancer
Epigenetics Discovery Performance Unit, Oncology Research & Development, ‡Protein Dynamics
Discovery Performance Unit, Oncology Research & Development, and §Platform Technology
and Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, United States
| | - Elsie Diaz
- Cancer
Epigenetics Discovery Performance Unit, Oncology Research & Development, ‡Protein Dynamics
Discovery Performance Unit, Oncology Research & Development, and §Platform Technology
and Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, United States
| | - Yong Jiang
- Cancer
Epigenetics Discovery Performance Unit, Oncology Research & Development, ‡Protein Dynamics
Discovery Performance Unit, Oncology Research & Development, and §Platform Technology
and Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, United States
| | - Neil W. Johnson
- Cancer
Epigenetics Discovery Performance Unit, Oncology Research & Development, ‡Protein Dynamics
Discovery Performance Unit, Oncology Research & Development, and §Platform Technology
and Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, United States
| | - Steven D. Knight
- Cancer
Epigenetics Discovery Performance Unit, Oncology Research & Development, ‡Protein Dynamics
Discovery Performance Unit, Oncology Research & Development, and §Platform Technology
and Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, United States
| | - Ryan G. Kruger
- Cancer
Epigenetics Discovery Performance Unit, Oncology Research & Development, ‡Protein Dynamics
Discovery Performance Unit, Oncology Research & Development, and §Platform Technology
and Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, United States
| | - Michael T. McCabe
- Cancer
Epigenetics Discovery Performance Unit, Oncology Research & Development, ‡Protein Dynamics
Discovery Performance Unit, Oncology Research & Development, and §Platform Technology
and Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, United States
| | - Dashyant Dhanak
- Cancer
Epigenetics Discovery Performance Unit, Oncology Research & Development, ‡Protein Dynamics
Discovery Performance Unit, Oncology Research & Development, and §Platform Technology
and Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, United States
| | - Peter J. Tummino
- Cancer
Epigenetics Discovery Performance Unit, Oncology Research & Development, ‡Protein Dynamics
Discovery Performance Unit, Oncology Research & Development, and §Platform Technology
and Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, United States
| | - Caretha L. Creasy
- Cancer
Epigenetics Discovery Performance Unit, Oncology Research & Development, ‡Protein Dynamics
Discovery Performance Unit, Oncology Research & Development, and §Platform Technology
and Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, United States
| | - William H. Miller
- Cancer
Epigenetics Discovery Performance Unit, Oncology Research & Development, ‡Protein Dynamics
Discovery Performance Unit, Oncology Research & Development, and §Platform Technology
and Sciences, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 19426, United States
| |
Collapse
|